BioSpace News Archive

Science Translational Medicine has published the results of a Duke University-led preclinical hamster transmission study that found that Vaxart’s (NASDAQ: VXRT) S-only oral COVID-19 vaccine candidate inhibited the transmission of SARS-CoV-2.

Aileron Therapeutics Announces First Patients Treated in Phase 1b Trial of ALRN-6924 in Patients with p53-Mutated Neoadjuvant Breast Cancer.

Mevion Medical Systems announced that it has been selected to install a MEVION S250i Proton Therapy System® with HYPERSCAN® Pencil Beam Scanning in a comprehensive hospital in Southern China.

Company Gave Three Presentations, Including Oral Discussion on How New Technology Can Support the “Just-in-Time” Approach to Biobanking.

Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of ocular diseases, today announced that Parisa Zamiri, MD, PhD, Chief Medical Officer of Graybug Vision, will present an update on the clinical development plan for GB-102 in wet age-related macular degeneration, and will be part of a subsequent panel discussion at the upcoming Clinical Trials at the Summit Meeting.

Ultragenyx Pharmaceutical Inc. announced positive longer-term efficacy and safety data from Phase 1/2 studies of DTX401 for the potential treatment of Glycogen Storage Disease Type Ia and DTX301 for the potential treatment of Ornithine Transcarbamylase deficiency.

Sterigenics®, a business of Sotera Health, and a global leader in comprehensive sterilization services, announced the beginning of processing at its expanded electron beam facility located in Columbia City, Indiana.

Biomea Fusion, Inc. (Nasdaq: BMEA), announced the nomination of its second product candidate, BMF-500, a highly selective and potent covalent investigational third-generation FLT3 inhibitor.

Sartorius, a leading international partner of life science research and the biopharmaceutical industry, is further growing its global production capacity with the expansion of its manufacturing site in Tunisia.

I-Mab (the “Company”) (Nasdaq” IMAB), today announced that it will hold a call with investors at 8 a.m. EST on May 27th to present preliminary data from an ongoing phase 2 clinical trial of its differentiated CD73 antibody uliledlimab (also known as TJD5, or TJ004309) and the global clinical development plan.